Royalty Pharma plc
Last updated September 27, 2026
Organization details
- Legal name
- Royalty Pharma plc
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- RPRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001802768
Board of directors
-
Bonnie L. Bassler · DirectorSince 2023
-
Carole Ho · DirectorSince 2025
-
Catherine M. Engelbert · DirectorSince 2023
-
David C. Hodgson · DirectorSince 2023
-
Elizabeth H. Weatherman · DirectorSince 2025
-
Errol B. Desouza · DirectorSince 2023
-
Gregory Norden · DirectorSince 2023
-
Henry A. Fernandez · DirectorSince 2023
-
Mario Germano Giuliani · DirectorSince 2023
-
Pablo G. Legorreta · Director · CEO, Chairman of the BoardSince 2023
-
Rory B. Riggs · DirectorSince 2023
-
Ted W. Love · DirectorSince 2023
-
Vlad Coric · DirectorSince 2025
Chief executives
Pablo G. Legorreta
· CEO, Chairman of the Board
Dates unknown
Board connections
12 of this board's directors also sit on 18 other boards.
- via Errol B. Desouza
- via David C. Hodgson
- via Carole Ho
- via Vlad Coric
- via Rory B. Riggs
- via Ted W. Love
- via Elizabeth H. Weatherman
- via Ted W. Love
- via Errol B. Desouza
- via Henry A. Fernandez
- via Catherine M. Engelbert
- via Gregory Norden
- via Pablo G. Legorreta
- via Bonnie L. Bassler
- via Ted W. Love
- via David C. Hodgson
- via Vlad Coric
- via Gregory Norden
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $92,348,629
- 72 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Open-market sale | −96,073 | $58.51 | $5,621,692 |
| Sep 22, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Open-market sale | −3,927 | $58.93 | $231,403 |
| Aug 19, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Gift | −16,800 | — | — |
| Aug 18, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Open-market sale | −100,000 | $59.97 | $5,997,250 |
| Aug 13, 2026 | Coyne Terrance P. Officer (EVP & CFO) | Open-market sale | −9,230 | $58.59 | $540,752 |
| Aug 13, 2026 | Coyne Terrance P. Officer (EVP & CFO) | Open-market sale | −1,772 | $59.14 | $104,799 |
| Aug 5, 2026 | Coyne Terrance P. Officer (EVP & CFO) | Grant or award | +11,002 | — | — |
| Aug 5, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Grant or award | +11,002 | — | — |
| Aug 5, 2026 | Pablo G. Legorreta Director, Officer (CEO, Chairman of the Board) | Grant or award | +65,216 | — | — |
| Aug 5, 2026 | Urist Marshall Officer (EVP, Research & Investments) | Grant or award | +8,252 | — | — |
| Jul 1, 2026 | Urist Marshall Officer (EVP, Research & Investments) | Open-market sale | −9,099 | $55.88 | $508,454 |
| Jun 30, 2026 | Bonnie L. Bassler Director | Grant or award | +689 | $54.40 | $37,482 |
| Jun 30, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Open-market sale | −97,446 | $56.50 | $5,505,972 |
| Jun 30, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Open-market sale | −2,554 | $57.10 | $145,841 |
| Jun 30, 2026 | Christopher Hite Officer (EVP & Chairman, Partnering) | Open-market sale | −29,400 | $56.44 | $1,659,404 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.